SUBSCRIBE
SUBSCRIBE
News   FDA

EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO

July 6, 2010 | 
1 min read
ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
FDA Approvals Europe
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
Creative development success and Innovation breakthrough progress as a Business advancement concept or growth strategy for taking off as a motivational metaphor for adaptation and goals focus.
Rare diseases
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
September 21, 2026
 · 
6 min read
 · 
Heather McKenzie
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Approvals
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
September 18, 2026
 · 
3 min read
 · 
Tristan Manalac